Metastatic Colorectal Cancer Market Poised for Expansion Across the 7MM During the Forecast Period (2025-2034) as Breakthrough Therapies Gain Traction
The metastatic colorectal cancer (mCRC) market is experiencing significant growth, driven by advancements in targeted therapies, immunotherapies, and personalized medicine. The increasing prevalence of colorectal cancer, along with growing awareness of early diagnosis and treatment options, is fueling demand for innovative treatments.
LAS VEGAS, April 23, 2025 /PRNewswire/ — Colorectal cancer (CRC) ranks as the third most prevalent cancer, with metastasis being the leading cause of mortality among affected patients. The liver and peritoneum are the most frequent sites of distant spread. For most individuals, metastatic CRC (mCRC) remains largely incurable, with common metastatic locations including the liver, lungs, lymph nodes, and peritoneum.
Seen in approximately 45% CRC patients, KRAS mutations significantly influence the prognosis and treatment outcomes. These mutations are associated with a more aggressive disease course, resistance to chemotherapy and targeted therapies, and overall poorer survival rates.
In 2024, the incidence of metastatic colorectal cancer was around 294K cases across the seven major markets, with the United States reporting the highest incidence. This number is expected to rise by 2034. Surgical intervention is the mainstay for resectable CRC, while unresectable cases are typically managed with chemotherapy, radiotherapy, and immunotherapy. These conventional therapies, however, often lack specificity and can harm healthy cells, leading to additional health complications.
The treatment paradigm for mCRC involves multiple lines of therapy. First-line (1L) metastatic colorectal cancer treatments include combination chemotherapy regimens such as FOLFOX, FOLFIRI, and CAPEOX, alongside anti-angiogenic agents and targeted therapies like VECTIBIX and ERBITUX, with or without chemotherapy. KEYTRUDA and BRAFTOVI (in combination with ERBITUX and mFOLFOX6) are also approved for use in the first line. In the second-line (2L) setting, treatment options expand to include OPDIVO (± YERVOY), JEMPERLI, TUKYSA (± Trastuzumab), LONSURF (± Bevacizumab), and KRAZATI plus ERBITUX. For third-line (3L) therapy, specific agents such as STIVARGA and FRUZAQLA are utilized.
Learn more about the metastatic colorectal cancer treatment landscape @ Metastatic Colorectal Cancer Drugs Market
FRUZAQLA (fruquintinib) is a once-daily oral capsule developed by Takeda Pharmaceuticals. It is a kinase inhibitor approved for adult patients with metastatic colorectal cancer who have previously been treated with chemotherapy regimens including fluoropyrimidine, oxaliplatin, and irinotecan, as well as anti-VEGF therapy and, for RAS wild-type patients, anti-EGFR therapy. FRUZAQLA works by selectively targeting and inhibiting VEGFR-1, -2, and -3, thereby disrupting VEGF-driven blood vessel formation and tumor growth.
The FDA approved FRUZAQLA for previously treated mCRC in November 2023, followed by the European Commission in June 2024, and Japan in September 2024—marking it as the first new targeted therapy for mCRC in more than ten years in the Japanese market.
OPDIVO QVANTIG (nivolumab and hyaluronidase-nvhy) is indicated for adult patients with MSI-H or dMMR mCRC that has progressed after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan. It can be used as a standalone treatment or following prior combination therapy with intravenous nivolumab and ipilimumab. This drug works by blocking the PD-1 receptor, preventing its interaction with PD-L1 and PD-L2 to boost immune system activity against cancer cells.
In December 2024, the FDA approved OPDIVO QVANTIG as a subcutaneous injection for mCRC, making it the first PD-1 inhibitor available in this form. This new route of administration offers quicker treatment delivery—just 3 to 5 minutes—compared to the traditional 30-minute intravenous infusion of OPDIVO.
To know more about metastatic colorectal cancer treatments, visit @ Metastatic Colorectal Cancer Aggressive Treatment
Despite several advancements, the metastatic colorectal cancer drug market remains highly competitive, with significant unmet needs for durable and long-term treatment responses. Ongoing research into investigational agents like amivantamab, zanzalintinib, and vactosertib highlights the push for more effective, resistance-targeting, and tumor microenvironment-modifying therapies, signaling a dynamic and evolving future for mCRC treatment.
Key companies such as Johnson & Johnson Innovative Medicine, Shanghai Henlius Biotech, Inspirna, Treos Bio, Cardiff Oncology, Agenus, Leap Therapeutics, Arcus Biosciences, Enterome, Tizona Therapeutics, Innovative Cellular Therapeutics, and others are currently active in the metastatic colorectal cancer drug market.
Discover which therapies are expected to grab major metastatic colorectal cancer drug market share @ Metastatic Colorectal Cancer Market Report
Amivantamab is a bispecific antibody designed to target specific genetic alterations, especially EGFR exon 20 insertion mutations. Its dual mechanism focuses on inhibiting both the Epidermal Growth Factor Receptor (EGFR) and the MET receptor—two key players in cancer cell growth and survival. By binding to these receptors, amivantamab interferes with their signaling pathways, helping to overcome resistance that tumors often develop to other treatments.
This dual targeting not only suppresses tumor cell growth but also enhances the body's immune response, leading to greater cancer cell destruction. The drug is currently in Phase III clinical trials for treating metastatic colorectal cancer (mCRC).
Zanzalintinib (XL-092) is a third-generation oral tyrosine kinase inhibitor that blocks several cancer-related receptor tyrosine kinases, including VEGF receptors, MET, AXL, and MER. These kinases play a role in normal cell function as well as pathological processes like cancer development, metastasis, angiogenesis, and resistance to therapies such as immune checkpoint inhibitors. Developed by Exelixis, Zanzalintinib builds on the company's experience with cabozantinib, aiming to improve attributes like pharmacokinetic half-life. It is also in Phase III clinical trials for mCRC.
DKN-01 is a humanized monoclonal antibody that targets the DKK1 protein and is being developed for treating esophagogastric, gynecologic, and colorectal cancers. Initial findings from Part A of the DeFianCe trial were shared at the 2024 ASCO Gastrointestinal Cancers Symposium. Enrollment for Part B of the DeFianCe trial (NCT05480306) concluded in September 2024. This Phase II, randomized, open-label, controlled study is assessing DKN-01 in combination with bevacizumab and chemotherapy as a second-line treatment for advanced colorectal cancer in patients previously treated with one systemic therapy. The study enrolled 188 patients, with early results anticipated by mid-2025.
Discover more about drugs for metastatic colorectal cancer in development @ Metastatic Colorectal Cancer Clinical Trials
The anticipated launch of these emerging metastatic colorectal cancer treatments are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the metastatic colorectal cancer market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
DelveInsight estimates that the market size for metastatic colorectal cancer in the 7MM is expected to grow from USD 13 billion in 2024 with a significant CAGR by 2034. This growth is fueled by advancements in precision medicine, including targeted therapies and immunotherapies, which have shown promise in improving patient outcomes.
DelveInsight's latest published market report titled as Metastatic Colorectal Cancer Market Insight, Epidemiology, and Market Forecast – 2034 will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the metastatic colorectal cancer country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The metastatic colorectal cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into:
Total Incident Cases of CRC
Gender-specific Cases of CRC
Age-specific Cases of CRC
Tumor Location-specific Cases of CRC
Stage-specific Cases of CRC
Total Incident Cases of mCRC
Mutation Type-specific Cases of mCRC
Total Treated Cases of mCRC by Line of Therapy
The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM metastatic colorectal cancer market. Highlights include:
10-year Forecast
7MM Analysis
Epidemiology-based Market Forecasting
Historical and Forecasted Market Analysis upto 2034
Emerging Drug Market Uptake
Peak Sales Analysis
Key Cross Competition Analysis
Industry Expert's Opinion
Access and Reimbursement
Download this metastatic colorectal cancer market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the metastatic colorectal cancer market. Also, stay abreast of the mitigating factors to improve your market position in the metastatic colorectal cancer therapeutic space.
Related Reports
Metastatic Colorectal Cancer Pipeline
Metastatic Colorectal Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key metastatic colorectal cancer companies, including Shanghai Henlius Biotech, Eisai Inc., Treos Bio, AUM Biosciences, Leap Therapeutics, Inc., Hoffmann-La Roche, Replimune, Qilu Pharmaceutical, Lutris Pharma, Ipsen, Bold Therapeutics, Pacylex Pharmaceuticals, FivepHusion, SystImmune, Inspirna, Inc., Sapience Therapeutics, Exelixis, Daiichi Sankyo, Hutchmed, Merus N.V., REVOLUTION Medicines, Pure Tech Health, Medicenna Therapeutics, Inc., Verastem Inc., Next Cure Inc., Isofol Medical, Zentalis Pharmaceuticals, Oncoinvent, KaryoPharm Therapeutics, Aadi Biosciences, among others.
Metastatic Colorectal Cancer Market
Metastatic Colorectal Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic colorectal cancer companies, including Johnson & Johnson Innovative Medicine, Shanghai Henlius Biotech, Inspirna, Treos Bio, Cardiff Oncology, Agenus, Leap Therapeutics, Arcus Biosciences, Enterome, Tizona Therapeutics, Innovative Cellular Therapeutics, among others.
Colorectal Cancer Market
Colorectal Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key colorectal cancer companies, including Mirati Therapeutics, Exelixis, Enterome, Arcus Biosciences, Lyell Immunopharma, AstraZeneca, Novartis Pharmaceuticals, Surgimab, Numab Therapeutics, SOTIO Biotech, Amgen, Sichuan Baili Pharmaceutical, Qilu Pharmaceutical, Bristol-Myers Squibb, NGM Biopharmaceuticals, Takeda, PureTech, Pfizer, Kezar Life Sciences, Salubris Biotherapeutics, among others.
Colorectal Cancer Pipeline
Colorectal Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key colorectal cancer companies, including Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, Lyell Immunopharma, Genentech, Cantargia AB, Arcus Biosciences, Inc, Neogap Therapeutics AB, Criterium, Inc, Daiichi Sankyo, Inc, Bristol-Myers Squibb, Celyad Oncology SA, Pfizer, Akeso, Menarini Group, Elpiscience (Suzhou) Biopharma, Ltd., BeyondBio Inc., Shanghai Henlius Biotech, Rottapharm Biotech, Innovative Cellular Therapeutics Inc., BioNTech SE, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur info@delveinsight.com +14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/metastatic-colorectal-cancer-market-poised-for-expansion-across-the-7mm-during-the-forecast-period-20252034-as-breakthrough-therapies-gain-traction–delveinsight-302435419.html
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
6 hours ago
- Malaysian Reserve
FIREHOOK OF VIRGINIA ISSUES ALLERGY ALERT ON UNDECLARED SESAME IN CLASSIC SEA SALT CRACKERS
CHANTILLY, Va., June 4, 2025 /PRNewswire/ — Firehook of Virginia is recalling one lot of Firehook brand Classic Sea Salt Organic Crackers because they may contain undeclared sesame. People who have an allergy or severe sensitivity to sesame run the risk of serious or life-threatening allergic reaction if they consume these products. The Firehook artisan baked Classic Sea Salt Crackers 8oz come in a clear package with a Best By Date of 09/29/25, and a UPC code 8 99055 00063 5. The crackers were sold at retail stores in CT, MA, MD, ME, NC, NH, NJ, NY, PA, RI, and VA. The recall was initiated on 5/30/2025 after it was discovered that the sesame-containing product was distributed in packaging that did not reveal the presence of sesame. Subsequent investigation indicates that the problem was caused by a temporary breakdown in the company's production and packaging processes causing the wrong labels to be applied to the product. No illnesses have been reported to date in connection with this problem. Please see the pictures below for further identification. Consumers who have purchased 8 ounce packages of Firehook brand Classic Sea Salt Crackers with a Best By Date of 9/29/25 are urged to return them to the place of purchase for a full refund. Consumers with questions may contact the company at 1-888-580-0745 Monday – Friday 8:00 am – 4:00 pm EST. Company Contact: Brent Fowler 1-888-580-0745
Malaysian Reserve
6 hours ago
- Malaysian Reserve
AI and Sustainability: Akkodis showcases the future of sustainable and digital innovation at the Paris Air Show 2025
The Smart Industry leader supports major companies in the aviation, aerospace and defense industry with digital transformation and invites visitors to discover the latest digital engineering trends at the air show. PARIS, June 5, 2025 /PRNewswire/ — Akkodis, a global digital engineering company and part of the Adecco Group, presents innovations to integrate AI and sustainability in the aviation, aerospace and defense sectors at the world-famous 55th Paris Air Show at the Le Bourget Parc des Expositions. Visitor experience With more than four decades of expertise in engineering, research & development (ER&D), Akkodis will offer visitors to its Chalet (#303 – line B) an experiential and immersive journey, an inspiring conference program and two expert publications on the topic of augmented engineering, as well as inclusion and diversity in engineering. The Chalet also features an AI Path and a Sustainability area, showcasing Akkodis' 360-degree product lifecycle capabilities, from ER&D to manufacturing and operations, IT and ecosystem support. 'Akkodis is sending a powerful message to the industry by bringing its full capacity to the Paris Air Show 2025 to showcase its pioneering technologies. We are here to help our clients in the aviation, aerospace and defense sector to unlock their full potential with the best tech consultants and ER&D solutions. As a trusted partner, our clients can count on our deep expertise and game-changing solutions to realize their ambition. We are committed to leveraging our full tech partnership ecosystem to support our clients in their value creation efforts', comments Jo Debecker, President and CEO of Akkodis. AI Path & Sustainability Area The event embodies excellence, innovation, and international cooperation in the fields of aviation and space. Following the idea of the 55th edition of Paris Air Show to serve as a global meeting place for excellence and innovation, Akkodis is putting the spotlight on two major pillars of transformation in the sector: – The integration of AI for performance through an interactive animation illustrating an optimization solution for aircraft maintenance, a helicopter cockpit simulator that makes it easier for pilots to get started, and a demonstration of a drone surveillance mission in the metaverse. – The challenge of a sustainable industry – Manufacturers are not only focused on the decarbonisation of aviation, but also in the green and responsible evolution of their entire value chain, supply chain and organisation. These issues will be highlighted through several scale models of devices, 3D models and animations on tablets. Akkodis is leveraging its strong technology ecosystem at the show. For example, attendees will learn how Akkodis and our global technology partner Microsoft are using AI technology to unlock solutions for the sector. 'In our second appearance at the Paris Air Show under the Akkodis brand, I am very proud to present the expertise and innovative spirit that our 9.000 employees in France demonstrate on a daily basis – they are shaping a more efficient, more connected and more sustainable future of aeronautics, aerospace and defense throughout the value chain. The Akkodis DNA is historically linked to these three industries and the technological innovations presented this year at the Paris Air Show are direct responses needed to support them in their transformation', says Yves-Marie BOISSONNET, President France and South EMEA Akkodis. Media contacts Anne Friedrich SVP, Global Head of Communications, Akkodis E. Ariane Olleris Manager External Communications The Adecco GroupE. About Akkodis Akkodis is a global digital engineering company and Smart Industry leader. We enable clients to advance in their digital transformation with Consulting, Solutions, Talent, and Academy services. Headquartered in Switzerland and part of the Adecco Group, Akkodis is a trusted tech partner to the world's industries. We co-create and pioneer solutions that help to solve major challenges, from accelerating the clean energy transition and green mobility, to improving user and patient centricity. Empowered by a culture of inclusion and diversity, our 50,000 tech experts across 30 countries combine best-in-class technologies and cross industry knowledge to drive purposeful innovation for a more sustainable tomorrow. We are passionate about Engineering a Smarter Future Together. | LinkedIn | Instagram | Facebook Twitter About the Adecco Group The Adecco Group is the world's leading talent company. Our purpose is making the future work for everyone. Through our three global business units – Adecco, Akkodis and LHH – across 60 countries, we enable sustainable and lifelong employability for individuals, deliver digital and engineering solutions to power the Smart Industry transformation and empower organisations to optimise their workforces. The Adecco Group leads by example and is committed to an inclusive culture, fostering sustainable employability, and supporting resilient economies and communities. The Adecco Group AG is headquartered in Zurich, Switzerland (ISIN: CH0012138605) and listed on the SIX Swiss Exchange (ADEN). Photo – – View original content:
Malaysian Reserve
6 hours ago
- Malaysian Reserve
Britive Helps to Pioneer the Future of Agentic Identity and Security Platform (AISP) Category, as identified by Aragon Research
Independent Research Firm Highlights Urgent Need to Secure Proliferating AI Agents and Agentic Systems; Forecasts AISP Market to Reach $32.9 Billion by 2031 GLENDALE, Calif., June 4, 2025 /PRNewswire/ — Britive, a leading innovator in identity security and the pioneer of the true zero-standing access technologies, is now helping to establish the emerging Agentic Identity and Security Platform (AISP) category, a role identified by Aragon Research in a new 2025 research note. The research note, 'The Rise of Agentic Identity and Security Platforms: The Must-Have Add-on for AI Agents and Agentic Systems,' by Aragon Research CEO and Lead Analyst Jim Lundy, highlights the urgent need for purpose-built solutions to secure the rapidly expanding landscape of AI agents and agentic systems within enterprises. The Aragon Research note underscores that, as 'Digital Labor is being powered by AI Agents and emerging Agentic AI Systems, which are digital workers that can do full job roles,' traditional security frameworks are ill-equipped to manage their dynamic behaviors and unique vulnerabilities. This creates a significant 'Access-Trust Gap' and introduces new risks such as prompt injection, over-permissioning, and unmanaged 'Shadow AI agent' sprawl. Aragon Research forecasts the AISP market will grow from $3.2 billion in 2025 to $32.9 billion by 2031, a 48.8% CAGR. 'The proliferation of AI agents is fundamentally transforming enterprise operations, it also introduces a critical new frontier of cybersecurity risk that cannot be ignored,' said Art Poghosyan, CEO of Britive. 'We are honored that Aragon Research has highlighted Britive's pioneering efforts in defining and addressing this urgent market need for Agentic Identity and Security Platforms. Britive was born for the cloud era; our platform's core capabilities have been shaped by direct feedback and real-world challenges faced by our highly regulated and innovative enterprise and Fortune 500 customers. This ensures we effectively enforce ephemeral, least-privilege access at runtime, a cornerstone for Zero Trust security strategy. Our patented Just-in-Time Zero Standing Privileges model, tested and proven in these demanding environments, naturally extends to secure autonomous agents without slowing innovation.' The Aragon Research note outlines six key elements of AISP: Agent Identity and Access Management Data and Knowledge Protection Agentic Operational Integrity and Resilience Agentic Governance, Risk and Compliance Policy Engine with Runtime Enforcement Human Oversight, Accountability and Attribution Britive's cloud-native platform is uniquely positioned to deliver on these requirements by: Extending True Zero Standing Privileges (ZSP) to AI Agents and Agentic Identities: Utilizing our patented Just-in-Time (JIT) access to ensure AI agents receive ephemeral, least-privilege access only when needed for specific tasks. Unifying Identity Governance: Providing a single platform to manage and audit privileges for humans, machines, and now AI agents, across multi-cloud, SaaS, and hybrid environments. Enabling Secure Agility for AI Initiatives: Leveraging an agent-less, proxy-less, and API-first architecture to seamlessly integrate security into AI agent workflows without hindering innovation or operational speed. 'The explosion of AI Agents and Agentic Systems in enterprises means a new level of risk that must be secured,' states the Aragon Research note. 'By making AISP part of every AI Agent and Agentic deployment, the enterprise can be assured that their information, data, and IP are protected.' Drawing on deep experience and feedback from leading enterprises in highly regulated and innovative sectors, Britive aims to help organizations confidently embrace AI-driven automation. The company's pioneering security framework is built for the new era of digital labor, delivering the unified visibility, security by design, and enterprise-grade speed and agility that modern challenges demand. To download a complimentary copy of the Aragon Research note, 'The Rise of Agentic Identity and Security Platforms,' visit Britive's website. About Britive Britive is a leading innovator in identity security and the pioneer of the first true zero-standing Privileged Access Management (PAM) platform, purpose-built to deliver unmatched speed and agility for today's dynamic multi-cloud and hybrid enterprises. Designed for the cloud era, not retrofitted from legacy systems, our patented approach eliminates standing access risks across all identities (human, machine, and AI agents), enabling secure innovation. Britive's API-first, agent-less architecture further unifies identity governance across all cloud platforms, SaaS, and on-premises systems via a single, centralized platform, ensuring clarity, confident compliance, and true operational agility. About Aragon Research: Aragon Research is an independent research and advisory firm that provides business and tech executives with the actionable insights they need to navigate technology's evolving impact on business. Aragon Research delivers high-impact visual research, consulting, and advisory services to provide enterprises with the insight they need to make better technology and strategy decisions. For more information, visit Contact Miad Moussawi VP of Marketing
